PAM and non-small cell lung carcinoma: First, we selected NSCLC patients who had received radiotherapy or chemotherapy in the TCGA and GEO databases as research subjects and screened out 10 GRGs (ACSS1, ERO1A, GPC4, PKP2, TXN, MERTK, ZNF292, ALDH3B2, PAM, RRAGD), and two clusters were identified based on their expression levels, which were significantly different in overall survival.